Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03875859 · ClinicalTrials.gov registry record · Phase 2
Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)
A Phase 2 study, sponsored by Kavita Sarin.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03875859: Clinical Trial Phase 2 study, sponsored by Kavita Sarin.
NCT03875859 is a Phase 2 study that was terminated before completion, run by Kavita Sarin. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03875859, a Phase 2 study, was terminated before completion, sponsored by Kavita Sarin.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied three times daily will suppress Squamous Cell Carcinoma.
Primary Outcome
Overall response (OR) will be assessed in squamous cell carcinoma (SCC). Objective response (OR) will defined as the number of lesions with either a complete response (CR) or a partial response (PR) among all eligible and treated lesions, any time within 10 weeks. * Complete Response (CR) = Disappearance of target lesion * Partial Response (PR) = ≥ 30% decrease in the sum of the longest diameter of target lesion * Overall Response (OR) = CR + PR
Interventions
- DRUG Remetinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-12-12 |
| Est. Completion | 2021-01-30 |
| Phase | Phase 2 |
Why NCT03875859 stopped before completion
NCT03875859 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Remetinostat is the first listed.
NCT03875859 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03875859 about?
NCT03875859 is a clinical study titled "Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)". The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied three times daily will suppress Squamous Cell Carcinoma.
What is the current status of trial NCT03875859?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-12-12. Estimated completion is 2021-01-30.
What interventions are being tested in trial NCT03875859?
The interventions under investigation include: Remetinostat (DRUG).
Who is sponsoring clinical trial NCT03875859?
This trial is sponsored by Kavita Sarin, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03875859's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI